SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company that develops multi-specific, high-potency human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's programs are based on mechanisms of action that have achieved proof-of-concept in clinical trials. SAB Biotherapeutics focuses on developing product candidates for disease targets where a differentiated approach can be either first-in-class against novel targets or best-in-class against complex targets, including type 1 diabetes (T1D) and other autoimmune disorders. Its lead candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach aimed at delaying onset and potentially preventing disease progression of Stage 3 T1D patients. The company uses advanced genetic engineering and antibody science to develop a proprietary technology capable of producing disease-targeted hIgG in large quantities without human plasma donors. This technology utilizes the human immune response to generate novel therapeutic candidates. SAB Biotherapeutics has optimized genetic engineering in the development of transchromosomic cattle, or Tc-Bovine™, to produce hIgG, with its production platform driving IgG1 production across its pipeline. This differentiated approach using polyclonal antibodies has no biosimilar pathway. The proprietary platform can generate additional novel therapeutic candidates by utilizing the human immune response to generate the optimal repertoire of hIgG for drug targets. The drug development production system generates a diverse repertoire of specifically targeted, high-potency hIgGs that can bind to multiple sites on targeted immunogens.